# BriSTAR Immunotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bristar-immunotech

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.bristarimmunotech.com
- Total disclosed funding: $67M
- Latest round: Series C (Jul 6, 2026)
- Investors on record: 16

## About

Based in Beijing, China and founded in 2018, China Immunotech (Beijing) Biotechnology Co. Ltd., trading as BriSTAR Immunotech, operates as a cellular immunotherapy developer that focuses on biopharmaceutical research and development. The company's founder is an immunologist and professor at Tsinghua University in Beijing, Xueqiang Zhao. The company cooperates with Lu Daopei Medical Group, Peking University First Hospital and Beijing Cancer Hospital. The company has filed nearly 100 invention patents globally and been granted more than 10 Chinese invention patents and PCT patents. In July 2026, it raised over CNY 200 million in series C funding.

The company provides cellular immunotherapy products for cancer and other diseases. The company developed Synthetic TCR and Antigen Receptor (STAR) and enTCR-T technologies platforms. The STAR technology can improve T cell expansion and reduce T cell depletion, and prevent tumor recurrence. The enTCR-T technology is used for complete antigen epitope prediction, multi-HLA tetramer preparation, high-throughput T cell receptor screening and identification. The cellular immunotherapy product pipelines focus on hematological tumors, solid tumors, and viral infections.

The company generates revenue primarily through biotechnology research collaborations, licensing agreements, strategic partnerships, and technology development activities.

The company will use the series C funding to advance the registration and clinical development of the universal STAR-T core product YTS109, accelerate the construction of the In vivo STAR-T technology platform, and establish a commercialization system and global intellectual property layout. In the future,the company will continue to adhere to independent innovation, continuously investing in R&D around its strategic directions of universal cell therapy and In vivo cell therapy, building a globally competitive cell therapy innovation platform, and providing patients with more safe, effective, and affordable treatment options.

## Funding rounds

- Series C, Jul 6, 2026, $29M — Loyal Valley Capital, Fudan Innovation Centre
- Series B, Jul 18, 2022 — Lotus Lake Capital, T-Capital, Hankang Capital
- Series B, Oct 11, 2021, $31M — HighLight Capital, China Growth Capital, Vertex Ventures China, V Star Capital, Sangel Capital, Tao Capital, Fenghai Capital, Changkejin  Investment, Hankang Capital
- Series A, Mar 9, 2020, $6.4M — Zhejiang Huacheng Holdings Group, Hankang Capital, Grower Venture Capital
- Angel, Aug 30, 2018 — Lotus Lake Capital, Zhongguancun Development Venture

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Angel, Series B
- Zhongguancun Development Venture (https://capitalatlas.ai/funds/zhongguancun-development-venture) — Angel
- Zhejiang Huacheng Holdings Group — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A, Series B
- Grower Venture Capital (https://capitalatlas.ai/funds/grower-venture-capital) — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series B
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series B
- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series B
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series B
- Fenghai Capital (https://capitalatlas.ai/funds/fenghai-capital) — Series B
- Changkejin  Investment — Series B
- T-Capital — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Fudan Innovation Centre (https://capitalatlas.ai/funds/fudan-innovation-centre) — Series C